Article

Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010.

Sexually Transmitted Bacteria Reference Laboratory, Health Protection Agency, London, United Kingdom.
Eurosurveillance: bulletin europeen sur les maladies transmissibles = European communicable disease bulletin (Impact Factor: 4.66). 01/2011; 16(14).
Source: PubMed

ABSTRACT Successful treatment of gonorrhoea is the mainstay of public health control. Cefixime and ceftriaxone, highly active third generation cephalosporins, are today the recommended first-line agents in most countries and azithromycin is a second-line agent. However, there is increasing evidence of decreasing susceptibility and emergence of therapeutic failures. In this report two cases of clinical failure to cefixime are described, one of which additionally shows failure to azithromycin and selection of a less susceptible strain during treatment.

1 Follower
 · 
76 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: South Africa has a high burden of infectious diseases, including a large portion that are of bacterial origin. This section reviews the national burden of disease and levels of antibiotic resistance in common bacterial infections in the human population. The consequences of resistance on clinical outcomes, through either treatment failures or the development of more virulent infections, are largely unknown. The full impact of antibiotic resistance on health in South Africa therefore remains to be assessed.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 01/2011; 101(8 Pt 2):567-78. · 1.71 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Neisseria gonorrhoeae antimicrobial susceptibility is monitored in the European Union (EU) and the European Economic Area (EEA) by the European gonococcal antimicrobial surveillance programme (Euro-GASP). Results from 17 EU/EEA Member States in 2009 showed that 5% of isolates had decreased susceptibility to cefixime, an upward trend in the minimum inhibitory concentrations of ceftriaxone and a high prevalence of resistance to ciprofloxacin (63%)and azithromycin (13%). These results are of public health value and highlight the need for healthcare professionals to be aware of possible cefixime treatment failures. Euro-GASP is being implemented in additional EU/EEA Member States to achieve greater representativeness. In addition, Euro-GASP aims to set up a system which will allow biannual reporting of antimicrobial resistance in the EU/EEA, with a transition from centralised towards decentralised testing,and will link epidemiological data to laboratory data to enhance surveillance. The benefits of this approach include more timely detection of emerging trends in gonococcal resistance across the EU/EEA and the provision of a robust evidence base for informing national and European guidelines for therapy.
    Eurosurveillance: bulletin europeen sur les maladies transmissibles = European communicable disease bulletin 01/2011; 16(42). · 4.66 Impact Factor
  • Source
    Sexually Transmitted Infections 07/2011; 87(Suppl 1):A277-A277. DOI:10.1136/sextrans-2011-050108.429 · 3.08 Impact Factor

Preview

Download
0 Downloads
Available from